Overview
GLSI market data
Price History
GLSI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.43 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.51 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.78 – $34.10 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $240.3M · P/B 824.09.
Company News
Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027Benzinga · Aug 10, 2026, 10:07 AM
Greenwich LifeSciences Receives UK Regulatory Approval To Expand FLAMINGO-01 Phase III Trial With Royal Marsden CollaborationBenzinga · Jul 22, 2026, 10:07 AM
HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69Benzinga · Jul 21, 2026, 5:03 PM
Greenwich LifeSciences shares are trading lower after the company provided clinical updates on FLAMINGO-01.Benzinga · Jul 20, 2026, 6:03 PM
Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going ForwardBenzinga · Jul 20, 2026, 10:10 AM
Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In EuropeBenzinga · Jul 16, 2026, 11:31 AM
Greenwich LifeSciences shares are trading lower after the company reported worse-than-expected Q4 EPS results.Benzinga · Jun 2, 2026, 3:36 PM
Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) EstimateBenzinga · Jun 1, 2026, 9:50 PM
Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026Benzinga · Jun 1, 2026, 12:19 PM
Greenwich LifeSciences Provides Update Regarding Form 10-K FilingGlobenewswire Inc · Jun 1, 2026, 11:15 AM